Inclisiran in a real-world single-center registry of patients with very high atherosclerotic cardiovascular risk
Background: A mean relative 50 % reduction of LDL cholesterol (LDLc) levels was observed in randomized studies in patients treated with inclisiran, a small-interfering-RNA therapeutic agent that reduces hepatic synthesis of PCSK9. Less is known on real world and every-day practice patients. Methods:...
Tallennettuna:
| Päätekijät: | , , , , , , , , , |
|---|---|
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
Elsevier
2025-09-01
|
| Sarja: | Atherosclerosis Plus |
| Aiheet: | |
| Linkit: | http://www.sciencedirect.com/science/article/pii/S2667089525000215 |
| Tagit: |
Ei tageja, Lisää ensimmäinen tagi!
|